Illumina (BSP:I1LM34) FCF Margin % : 26.30% (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Illumina FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Illumina's Free Cash Flow for the three months ended in Sep. 2024 was R$1,573 Mil. Illumina's Revenue for the three months ended in Sep. 2024 was R$5,981 Mil. Therefore, Illumina's FCF Margin % for the quarter that ended in Sep. 2024 was 26.30%.

As of today, Illumina's current FCF Yield % is 2.33%.

The historical rank and industry rank for Illumina's FCF Margin % or its related term are showing as below:

BSP:I1LM34' s FCF Margin % Range Over the Past 10 Years
Min: -1.61 Med: 20.82 Max: 28.96
Current: 12.63

During the past 13 years, the highest FCF Margin % of Illumina was 28.96%. The lowest was -1.61%. And the median was 20.82%.

BSP:I1LM34's FCF Margin % is ranked better than
80.56% of 216 companies
in the Medical Diagnostics & Research industry
Industry Median: -5.655 vs BSP:I1LM34: 12.63

Illumina FCF Margin % Historical Data

The historical data trend for Illumina's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Illumina FCF Margin % Chart

Illumina Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

23.77

27.51

7.45

-1.61

6.26

Illumina Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial															8.49	15.33	3.81	4.41	26.30

Competitive Comparison of Illumina's FCF Margin %

For the Diagnostics & Research subindustry, Illumina's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Illumina's FCF Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Illumina's FCF Margin % falls into.

Illumina FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Illumina's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	1381.743	/	22068.699
	=	6.26 %

Illumina's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	1572.735	/	5980.824
	=	26.30 %

Illumina FCF Margin % Related Terms

Thank you for viewing the detailed overview of Illumina's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Illumina Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Illumina Inc (BSP:I1LM34) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

ILMN:USA ILMN:Mexico 1ILMN:Italy 0J8Z:UK ILU:Germany ILU:Germany ILU:Germany ILMN:Austria

Address

5200 Illumina Way, San Diego, CA, USA, 92122

Website

https://www.illumina.com

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Illumina Headlines

No Headlines